Endurance Bio
Endurance Bio develops first-in-class small molecules, T-168 and T-621, designed to rejuvenate mitochondria and lysosomes. These compounds function by reducing oxidative stress and inflammation while enhancing cellular autophagy processes. The company is advancing T-168 into clinical trials for neurodegenerative diseases like Parkinson's and ALS, with broad potential across metabolic and aging-related conditions.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Endurance Bio develops first-in-class small molecules, T-168 and T-621, designed to rejuvenate mitochondria and lysosomes. These compounds function by reducing oxidative stress and inflammation while enhancing cellular autophagy processes. The company is advancing T-168 into clinical trials for neurodegenerative diseases like Parkinson's and ALS, with broad potential across metabolic and aging-related conditions.